Covidien News

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Covidien , a leading global provider of healthcare products, today announced that the U.S. Food and Drug Administration has set a new action date under the Prescription Drug User Fee Act for the review of the New Drug Application for Exalgo Tablets , of February 22, 2010.

Main Category: Pain / Anesthetics Also Included In: Regulatory Affairs / Drug Approvals Article Date: 18 Nov 2009 Covidien announced that on November 13, 2009, representatives of Neuromed discussed the pending New Drug Application for the product candidate ExalgoTM tablets with staff from the United States Food and Drug Administration .

Covidien said Tuesday that its fourth-quarter profit dropped to one-seventh of what it was a year ago due to charges related to divestitures and acquisitions, but also said it raised its sales-growth projection.

Our analysts have issued complimentary analysis on the following six companies: Chimera Investment Corporation , Lowe's Companies Inc.

A complete list of all headlines and biomedical stock developments can be found on BioMedReports.Com On 11/11/09, Covidien will present at the Lazard Capital Markets 6th Annual Healthcare Conference in New York on Wednesday, November 18, 2009.

NORTH HAVEN, Conn. - Covidien , a leading global provider of healthcare products, today announced the launch of DuraSeal spine sealant, the first product approved by the U.S. Food and Drug Administration for intra-operative sealing of the dural membrane during spine procedures.

Covidien , a leading global provider of healthcare products, today announced that it will voluntarily contraindicate the use of its OptimarkTM gadoversetamide injection, a gadolinium-based contrast agent , in magnetic resonance imaging procedures involving patients with severe renal impairment.

AUSTIN, Texas-- --Stratus Properties Inc. : HIGHLIGHTS On October 21, 2009, Stratus' joint venture with Canyon-Johnson Urban Fund II, L.P. closed on a $120 million co... SEATTLE-- --Online Banking Report announces a new in-depth research report that looks at how financial institutions can use online and mobile banking to attract small- and ...

Covidien , a leading global provider of healthcare products, today announced the successful completion of its tender offer through its subsidiary, Transformer Delaware Corp., to purchase all of the outstanding shares of common stock of Aspect Medical Systems, Inc.

For Richard Meelia, then president of billion-dollar medical devices and services maker Tyco Healthcare, 2002 turned into a long nightmare.

The Oral Transmucosal Fentanyl Citrate is an opiod analgesic designed for cancer patients to place inside the cheek for pain relief.

Covidien, a global provider of healthcare products, hasannounced that its subsidiary, Mallinckrodt Inc., has received U.S. Food and Drug Administration approval of its Abbreviated New Drug Application for Oral Transmucosal Fentanyl Citrate .

AllPennyStocks.com News: Safety Syringes & Color MRIs: Two Products Paving the Way for Advances in Medicine 10/28/2009 MISSISSAUGA, Ontario, October 28, 2009 -- AllPennyStocks.com Media, Inc.

First Citizens' Federal Credit Union has launched a new savings and checking program aimed at honoring men and women in the community who are providing extraordinary service to South Coast and Cape Cod cities and towns.

October 12, 2009 Emulex Corporation at $11.37 on a volume of 422,033 shares In a press release on October 12, Emulex First 8Gb/s Encryption HBA at RSA Conference Europe 2009 Host-Based Encryption Security Architecture Protects Data Throughout the Enterprise COSTA MESA, Calif., Oct 12, 2009 Emulex Corporation today announced that it will be ...

Houston - The stock market opened strong Monday morning, partially due to the recent activity in drug stocks with Abbot announcing its acquisition of Solvay's drug unit, Covidien's news of its acquisition of Aspect Medical Systems and Biocryst's move to phase 2 study.

Covidien , a leading global provider of healthcare products and recognized innovator in mechanical ventilation and respiratory care devices, today announced that it has received 510 clearance from the U.S. Food and Drug Administration to market its Mallinckrodta TaperGuarda Evac endotracheal tube.

Covidien plc has announced an agreement to buy Norwood-based brain-monitoring device company Aspect Medical Systems Inc.

On 5/26/09, Johnson & Johnson announced that the FDA extended by three months the review timeline for the Biologic License Application for Stelara to provide time for a full review of an amendment to the pending application.